Of the 4 clinical specimens with a suggested MET exon14 skipping event, two were melanoma samples, one of which also carried a driver NRAS mutation, one was a colorectal cancer and the last was a lung cancer sample with a KRAS driver mutation. This evidence concerns the gene MET and lung cancer.